Traditional and translational medicine;La médecine traditionnelle et la médecine translationnelle

Bulletin de l'Academie Nationale de Medecine

Volumn 191, Issue 4-5, 2007, Pages 715-726

  Godfraind, Théophile ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Biological markers; Chemistry; Drug evaluation trends; Pharmaceutical methods; Pharmacogenetics; Proteomics; Technology pharmaceutical; Toxicology methods

Indexed keywords

BIOLOGICAL MARKER;

CHEMISTRY; CLINICAL PHARMACOLOGY; DRUG SCREENING; EUROPE; EXPERIMENTAL THERAPY; HISTORY; HUMAN; METHODOLOGY; MOLECULAR BIOLOGY; PHARMACEUTICS; PHARMACOGENETICS; PROTEOMICS; REVIEW; TOXICOLOGY; TRADITIONAL MEDICINE; UNITED STATES;

BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION; EUROPE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; MEDICINE, TRADITIONAL; MOLECULAR BIOLOGY; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL; THERAPIES, INVESTIGATIONAL; TOXICOLOGY; UNITED STATES;

EID: 39549100368     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33005-5     Document Type: Article

References (28)

1. MARINCOLA F.M. -Translational Medicine : A two-way road. J. Transi Med., 2003, 1, 1.
2. DONNELLY F.A.J. -P. European Technology Platform on Innovative. Medicines Int. J. Pharm. Med., 2005, 19, 153-161.
3. PEARSON H. - The bitterest pill. Nature. 2006, 444, 532-533
4. GODFRAIND T. - La recherche de nouveaux médicaments ; de l'empirisme à la logique. Louvain, 1989, Nov. 89/3, 17-19.
5. DAFNI A., LEVY S., LEV E. - The ethnobotany of Christ's Thorn Jujube (Ziziphus spinachristi) in Israel. J. Ethnobiol. Ethnomedicine, 2005, 1, 8.
6. KRANTZ J.C. - Jr. Historical Medical Classics involving new drugs. Baltimore : The Williams & Wilkins Company, 1974.
7. BOVET D., BOVET-NITTI F. - Structure et activité pharmacodynamique des médicaments du système nerveux végétatif. Bâle-New York : S. Karger, 1948.
8. BLACK J.W. -Propranolol and Cimetidine. Verk K. Acad. Geneeskd. Belg. 1979, 41, 166-172
9. GODFRAIND T. -TiPS, a venture in pharmacology. Trends Pharmacol. Sci. 2004, 25, 167-169
10. GODFRAIND T., POLSTER P. -Étude comparative de médicaments inhibant la réponse contractile de vaisseaux isolés d'origine humaine ou animale. Thérapie, 1968, 23, 1209-1220
11. DUPUIS B. -Editorial Thérapie, 1993, 48, Spec. No 635-6.
12. GODFRAIND T., MILLER R., WIBO M. -Calcium antagonism and calcium entry blockade. Pharmacol. Rev., 1986, 38, 321-416.
13. GODFRAIND T. -Calcium Channel Blockers. Basel -Boston -Berlin : Birkhaäuser Verlag, 2004.
14. [14] BETZ H., LAUBE B. -Glycine receptors : recent insights into their structural organization and functional diversity. J. Neurochem., 2006, 97, 1600-1610 (Pubitemid 43873655)
15. [15] SIEST G., MARTEAU J.B., MAUMUS S. et al. -Pharmacogenomics and cardiovascular drugs : need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol., 2005, 527, 1-22. (Pubitemid 41745146)
16. PEREL P., ROBERTS I., SENA E. et al. -Comparison of treatment effects between animal experiments and clinical trials : systematic review. BMJ, 2006.
17. BOUREL M., ARDAILLOU R. -Pharmacogénétique et pharmacogénomique. Bull. Acad. Natle Méd., 2006, 190, 9-22, discussion 22-23
18. JAILLON P. -Tests pharmacogénétiques : leur place en pratique courante et dans le développement des médicaments. Bull Acad Natle Méd., 2006, 190, 25-34, discussion 34-36
19. LHERMITTE M., ALLORGE D., BROLY F. -Le polymorphisme géné tique des enzymes du métabolisme des médicaments. Une opportunité pour un traitement individualisé. Bull. Acad. Natle Med, 2006, 190, 55-69, discussion 69-73.
20. [20] KRAUSE D.S., VAN ETTEN R.A. -Tyrosine kinases as targets for cancer therapy. Ai Engl. J. Med., 2005, 353, 172-187 (Pubitemid 41058349)
21. [21] CROWDER R.J., LOMBARDI D.P., ELLIS M.J. -Successful targeting of ErbB2 receptors-is PTEN the key ? Cancer Cell, 2004, 6, 103-104 (Pubitemid 39485680)
22. [22] MOY B., Goss P.E. -Lapatinib : current status and future directions in breast cancer. Oncologist, 2006, 11, 1047-1057 (Pubitemid 44788395)
23. [23] KOCH W.H. -Technology platforms for pharmacogenomic diagnostic assays. Nat. Rev. Drug Discov., 2004, 3, 749-761 (Pubitemid 39242827)
24. [24] ARAB S., GRAMOLINI A.O., PING P. et al. -Cardiovascular proteomics : tools to develop novel biomarkers and potential applications. J. Am. Coll. Cardiol., 2006, 48, 1733-1741 (Pubitemid 44648616)
25. [25] HYE A., LYNHAM S., THAMBISETTY M. et al. - Proteome-based plasma biomarkers for Alzheimer's disease. Brain, 2006, 129, 3042-3050 (Pubitemid 44684524)
26. [26] FELLA K., GLUCKMANN M., HELLMANN J., KARAS M., KRAMER PJ., KROGER M. -Use of two-dimensional gel electrophoresis in predictive toxicology : identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics, 2005, 5, 1914-1927 (Pubitemid 40686236)
27. [27] WANG T.J., GONA P., LARSON M.G. et al. -Multiple biomarkers for the prediction of first major cardiovascular events and death. AC Engl. J. Med., 2006, 355, 2631-2639 (Pubitemid 44969122)
28. [28] Finishing the euchromatic sequence of the human genome. Nature, 2004, 431, 931-945 (Pubitemid 39434409)